Mounjaro 2.5 mg / 0.5 ml Injection

Mounjaro 2.5 mg / 0.5 ml Injection

Drug Name:

Mounjaro 2.5 mg

Categories: ,

International Brand: Mounjaro

Mounjaro

Details

Drug Name: Mounjaro 2.5 mg / 0.5 ml Injection (Tirzepatide)

Category: GLP-1 and GIP receptor agonist (antidiabetic medication)

International Brand: Mounjaro

Mounjaro offers tirzepatide, a dual receptor agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptidе-1 (GLP- It is intended to enhance blood sugar management in adults diagnosed with type 2 diabetes. Additionally, it aids in the Management of Obesity. This product may be a better alternative to Ozempic which contains Semaglutide. Ozempic (semaglutide) and Mounjaro (tirzepatide) are both injectable medications used to manage type 2 diabetes, and they belong to a similar class of drugs called GLP-1 receptor agonists (with Mounjaro also acting as a GIP receptor agonist).

Uses:

  • Boosts the level of blood sugar control in people with type 2 diabetes.
  • May help with weight management.
  • Lowers the risk of cardiovascular issues.
  • Used in conjunction with diet and exercise.
  • Delivered through subcutaneous injection.
  • Management of Obesity

How it Works: Tirzepatide activates both GLP-1 and GIP receptors, promoting insulin release, decreasing glucagon secretion, and slowing down digestion to enhance blood sugar regulation. And management of diet in adults.

Dosage:

  • Typically starts at 2.5 mg once a week.
  • Dosage can be modified based on the individual’s response.
  • dispensed through subcutaneous injection in the abdomen, thigh or upper arm.
  • Provided on the same weekly day.
  • Adhere closely to your healthcare provider’s instructions.

What if you forget to take the Mounjaro Solution for injection?

If a dose of Mounjaro 2.5 mg Solution for Injection is missed, take it as soon as possible within four days (96 hours). If more than four days have elapsed, forget the missed dose and continue with your regular regimen. The day of weekly administration may be adjusted if needed, provided there is at least a 3-day (72 hours) interval between doses.

Side Effects:

  • Nausea
  • Decreased dietary intake
  • Vomiting
  • Diarrhea
  • Lowered appetite
  • Abdominal discomfort
  • Reactions at the injection site

Precautions:

  • Not advised for type 1 diabetes or diabetic ketoacidosis.
  • Watch for signs of pancreatitis.
  • Exercise caution in individuals with a history of gastrointestinal issues.
  • The proper monitoring of kidney and liver function is necessary for optimal outcomes.
  • Not advised during pregnancy or while breastfeeding.

Contraindications:

  • Personal or family history of medullary thyroid carcinoma.
  • Allergic reaction to tirzepatide or any ingredient in Mounjaro.
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Interactions:

  • May slow gastric emptying, which can impact the absorption of oral medications.
  • Be cautious when used with other diabetes treatments (risk of hypoglycemia).
  • Possible interactions with insulin or sulfonylureas.
  • Consult with a healthcare provider prior to combining with other drugs.